Alex Arfaei of BMO Capital Markets upgraded Merck to "outperform" Thursday morning in a note sent to clients.
He is one of the top analysts on Wall Street covering Merck and the pharmaceuticals sector. Arfaei's picks average a 17.6 percent one-year return with an 84 percent success rate, according to TipRanks.com.
Here's why he likes Merck now…